230 related articles for article (PubMed ID: 18980468)
1. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin in cancer: a dilemma in risk therapy.
Cao Y
Trends Endocrinol Metab; 2013 Apr; 24(4):190-9. PubMed ID: 23218687
[TBL] [Abstract][Full Text] [Related]
3. [Use of erythropoietin in oncology].
Rosso R; Del Mastro L; Venturini M; Bergaglio M; Pasquetti W; Garrone O
Tumori; 1997; 83(4 Suppl 2):S26-30. PubMed ID: 9487381
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients.
Thomaidis T; Weinmann A; Sprinzl M; Kanzler S; Raedle J; Ebert M; Schimanski CC; Galle PR; Hoehler T; Moehler M;
Int J Clin Oncol; 2014 Apr; 19(2):288-96. PubMed ID: 23532629
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin or darbepoetin for patients with cancer.
Tonia T; Mettler A; Robert N; Schwarzer G; Seidenfeld J; Weingart O; Hyde C; Engert A; Bohlius J
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003407. PubMed ID: 23235597
[TBL] [Abstract][Full Text] [Related]
6. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy.
Flynn RW; Bonellie SR; Jung RT; MacDonald TM; Morris AD; Leese GP
J Clin Endocrinol Metab; 2010 Jan; 95(1):186-93. PubMed ID: 19906785
[TBL] [Abstract][Full Text] [Related]
7. Adverse events of erythropoietin in long-term and in acute/short-term treatment.
Singbartl G
Clin Investig; 1994; 72(6 Suppl):S36-43. PubMed ID: 7950171
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.
Aapro M; Moebus V; Nitz U; O'Shaughnessy J; Pronzato P; Untch M; Tomita D; Bohac C; Leyland-Jones B
Ann Oncol; 2015 Apr; 26(4):688-695. PubMed ID: 25542926
[TBL] [Abstract][Full Text] [Related]
9. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
[TBL] [Abstract][Full Text] [Related]
10. Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia.
Mountzios G; Aravantinos G; Alexopoulou Z; Timotheadou E; Matsiakou F; Christodoulou C; Laschos K; Galani E; Koutras A; Bafaloukos D; Linardou H; Pectasides D; Varthalitis I; Papakostas P; Kalofonos HP; Fountzilas G
Mol Clin Oncol; 2016 Feb; 4(2):211-220. PubMed ID: 26893865
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin and cancer: the unintended consequences of anemia correction.
Debeljak N; Solár P; Sytkowski AJ
Front Immunol; 2014; 5():563. PubMed ID: 25426117
[TBL] [Abstract][Full Text] [Related]
12. Amiodarone-induced thyroid dysfunction.
Danzi S; Klein I
J Intensive Care Med; 2015 May; 30(4):179-85. PubMed ID: 24067547
[TBL] [Abstract][Full Text] [Related]
13. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use.
Schrijvers D; De Samblanx H; Roila F;
Ann Oncol; 2010 May; 21 Suppl 5():v244-7. PubMed ID: 20555090
[No Abstract] [Full Text] [Related]
14. Erythropoietin in cancer patients: pros and cons.
Dicato M; Plawny L
Curr Opin Oncol; 2010 Jul; 22(4):307-11. PubMed ID: 20498598
[TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agents for anemic patients with cancer.
Sheikh S; Littlewood TJ
Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of cancer-related anemia.
Gilreath JA; Stenehjem DD; Rodgers GM
Am J Hematol; 2014 Feb; 89(2):203-12. PubMed ID: 24532336
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity in leukemia cells that escape drug-induced senescence-like state.
Miller D; Kerkhofs K; Abbas-Aghababazadeh F; Madahar SS; Minden MD; Hébert J; Haibe-Kains B; Bayfield MA; Benchimol S
Cell Death Dis; 2023 Aug; 14(8):503. PubMed ID: 37543610
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA.
Zuccarini A; Cicognini D; Tancredi R; Ferrari A; Rizzo G; Lasagna A; Caccialanza R; Cavanna L; Orlandi E; Biasini C; Molinaro P; Garigliano D; Costantino A; Moroni M; Perrone L; Alessio NL; Rovati B; Ferretti VV; Klersy C; Pedrazzoli P
Support Care Cancer; 2022 Sep; 30(9):7645-7653. PubMed ID: 35678882
[TBL] [Abstract][Full Text] [Related]
19. A New Inflammation-Related Risk Model for Predicting Hepatocellular Carcinoma Prognosis.
Xing M; Li J
Biomed Res Int; 2022; 2022():5396128. PubMed ID: 35572724
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin Promotes Infection Resolution and Lowers Antibiotic Requirements in
Liang F; Guan H; Li W; Zhang X; Liu T; Liu Y; Mei J; Jiang C; Zhang F; Luo B; Zhang Z
Front Immunol; 2021; 12():658715. PubMed ID: 33927725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
